conjugated estrogens/medroxyprogesterone (Prempro, Premphase)
Jump to navigation
Jump to search
Introduction
Premarin & Provera combination.
Indications
Contraindications
Dosage
0.625 mg of Premarin & 2.5 mg Provera
0.625 mg of Premarin & 5.0 mg Provera
0.45 mg of Premarin & 1.5 mg Provera[3]
0.3 mg of Premarin & 1.5 mg Provera[5]
Pharmacokinetics
elimination: liver
Adverse effects
- may increase risk of dementia in women > 65[3]
- relative risk is small; additional 23 cases/10,000/year
- mechanism may be via increase in ischemic stroke
- increased risk of urinary incontinence > 65[3]
- 3 fold increased risk urge incontinence
- 5-fold increased risk of stress incontinence
- increased risk of breast cancer in older women[4]
- breast cancer developing in women taking Prempro more difficult to detect by mammography due to increase in breast tissue radiographic density[4]
- continuous Progestin appears to be culprit
Mechanism of action
Also see hormone replacement therapy.
More general terms
Additional terms
Components
- conjugated estrogens (Premarin, Enjuvia, Cenestin)
- medroxyprogesterone actetate; acetoxymethylprogesterone (Provera, Cycrin, Amen)
References
- ↑ The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996
- ↑ Prescriber's Letter 7(7):40 2000
- ↑ 3.0 3.1 3.2 3.3 Prescriber's Letter 10(6):33,34 2003
- ↑ 4.0 4.1 4.2 Prescriber's Letter 10(8):47 2003
- ↑ 5.0 5.1 Prescriber's Letter 11(2):suppl 2004
- ↑ Department of Veterans Affairs, VA National Formulary